HIV/AIDS

Cerus Corporation Awarded Grants for Its Listeria-Based Vaccine Platforms

Published in AIDS Weekly, March 19th, 2007

Cerus Corporation (NASDAQ:CERS) announced the receipt of two research grants to develop vaccines based on its proprietary Listeria platforms. These grants fund early-stage work to develop vaccines to both treat and prevent infections caused by HCV and HIV.

The first grant, awarded to researches at Cerus and two collaborators from Johns Hopkins University (JHU) is entitled, "Development of Listeria-based Clinical Consensus HCV Vaccine Candidates." This grant was received from the National Institute of Allergy and Infectious Disease, a division of the National Institutes of Health.

The collaboration brings together HCV consensus sequence antigens...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2007-03-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry